Brian Mulherin, MD
Hematology & Oncology · Indianapolis, INNPI 1922034156
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.2%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Apellis Pharmaceuticals, Inc. at 49.7% of the total. Reporting peaked in 2023 at $94,535 and has fallen 73.5% since, to $25,012 in 2025. Among hematology & oncology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 345 payments — averaging $506.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Apellis Pharmaceuticals, Inc.$87K
- Novartis$32K
- Gilead$10K
- Incyte Corporation$7K
- Beigene USA, Inc.$4K
- Pharmacosmos Therapeutics Inc.$4K
- plus $30K from 54 others
Across 31 payments — averaging $65,396 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$2M
- AbbVie$15K
- Apellis Pharmaceuticals, Inc.$10K
- E.r. Squibb & Sons, L.L.C.$3K
- Pharmacyclics LLC, An Abbvie Company$1K
- Amgen$1K
What the payments were for
- Consulting fees$96,51355%
- Speaking & faculty fees$55,04031%
- Travel & lodging$15,6209%
- Food & beverage$6,8684%
- Education$1010%
- Other$5980%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$174,741 in reported general payments places this provider in the 95th percentile of 224 hematology & oncology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 92 | $1,641,819 |
| BrukinsaZanubrutinib | 59 | $857,481 |
| CalquenceAcalabrutinib Maleate | 40 | $612,745 |
| ErleadaApalutamide | 39 | $608,203 |
| EmpaveliPegcetacoplan | 13 | $490,702 |
| JaypircaPirtobrutinib | 15 | $337,361 |
| CabometyxCabozantinib S-Malate | 12 | $312,420 |
| JakafiRuxolitinib Phosphate | 18 | $306,439 |
| Lenalidomide | 20 | $273,760 |
| VenclextaVenetoclax | 30 | $262,649 |
| XtandiEnzalutamide | 16 | $226,243 |
| EliquisApixaban | 183 | $176,441 |
| TagrissoOsimertinib Mesylate | 11 | $163,733 |
| Abiraterone Acetate | 23 | $132,139 |
| GilotrifAfatinib Dimaleate | 11 | $110,687 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $92 | $1,641,81992 claims |
| Beigene USA, Inc.Brukinsa | $3,938 | $857,48159 claims |
| AstraZenecaCalquence, Tagrisso | $2,482 | $776,47851 claims |
| Johnson & JohnsonErleada, Xarelto | $2,810 | $680,188104 claims |
| Apellis Pharmaceuticals, Inc.Empaveli | $86,924 | $490,70213 claims |
| Lilly USA, LLCJaypirca | $194 | $337,36115 claims |
| Exelixis Inc.Cabometyx | $89 | $312,42012 claims |
| Incyte CorporationJakafi | $7,351 | $306,43918 claims |
| AbbVieVenclexta | $270 | $262,64930 claims |
| Astellas Pharma US IncXtandi | $103 | $226,24316 claims |
| PfizerEliquis | $298 | $176,441183 claims |
| Boehringer IngelheimGilotrif | $17 | $110,68711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 224 hematology & oncology providers in Indiana.
Other hematology & oncology in Indianapolis
- Richard GaynorIndianapolis$3.7M
- Ruemu BirhirayIndianapolis$3.1M
- Anand TandraIndianapolis$280K
- Attaya SuvannasankhaIndianapolis$253K
- Michael DuganIndianapolis$236K
- Daniel MiltonIndianapolis$231K
- Amro ElshouryIndianapolis$212K
- Muhammad Sarfraz NawazIndianapolis$172K
- John EdwardsIndianapolis$169K
- Karam Al-IssaIndianapolis$77K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.